Analysis of combination anti-angiogenesis therapy on markers of coagulation, platelet activation and angiogenesis in patients with advanced cancer
- 17 November 2004
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 219 (2) , 163-167
- https://doi.org/10.1016/j.canlet.2004.09.036
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Plasma angiopoietin‐1, angiopoietin‐2 and Tie‐2 in breast and prostate cancer: a comparison with VEGF and Flt‐1European Journal of Clinical Investigation, 2003
- Preoperative plasma concentrations of vascular endothelial growth factor and matrix metalloproteinase 9 are associated with stage progression in papillary thyroid cancerClinical Endocrinology, 2003
- Tissue specific expression and serum levels of human tissue factor in patients with urological cancerCancer Letters, 2003
- Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromesCancer, 2002
- Analysis of Coagulation Cascade and Endothelial Cell Activation During Inhibition of Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Pathway in Cancer PatientsArteriosclerosis, Thrombosis, and Vascular Biology, 2002
- Soluble P-selectin is influenced by cancer chemotherapyPlatelets, 2001
- Tissue factor expression and angiogenesisin human prostate carcinomaHuman Pathology, 2000
- Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats.Journal of Clinical Investigation, 1996
- In situ detection of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast diseaseNature Medicine, 1996
- Angiogenesis Inhibition and Tumor Regression Caused by Heparin or a Heparin Fragment in the Presence of CortisoneScience, 1983